Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

AzurRx BioPharma

DB:366
Snowflake Description

Mediocre balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
366
DB
$15M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. The last earnings update was 9 days ago. More info.


Add to Portfolio Compare Print
  • AzurRx BioPharma has significant price volatility in the past 3 months.
366 Share Price and Events
7 Day Returns
3%
DB:366
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-72.6%
DB:366
-7.4%
DE Biotechs
-14.2%
DE Market
366 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AzurRx BioPharma (366) 3% -22.4% -59.1% -72.6% - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 366 underperformed the Biotechs industry which returned -7.4% over the past year.
  • 366 underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
366
Industry
5yr Volatility vs Market
Related Companies

366 Value

 Is AzurRx BioPharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for AzurRx BioPharma. This is due to cash flow or dividend data being unavailable. The share price is €0.52.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AzurRx BioPharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AzurRx BioPharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:366 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.68
NasdaqCM:AZRX Share Price ** NasdaqCM (2020-04-08) in USD $0.56
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AzurRx BioPharma.

DB:366 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:AZRX Share Price ÷ EPS (both in USD)

= 0.56 ÷ -0.68

-0.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AzurRx BioPharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • AzurRx BioPharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does AzurRx BioPharma's expected growth come at a high price?
Raw Data
DB:366 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
39.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AzurRx BioPharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AzurRx BioPharma's assets?
Raw Data
DB:366 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.17
NasdaqCM:AZRX Share Price * NasdaqCM (2020-04-08) in USD $0.56
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:366 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:AZRX Share Price ÷ Book Value per Share (both in USD)

= 0.56 ÷ 0.17

3.25x

* Primary Listing of AzurRx BioPharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AzurRx BioPharma is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess AzurRx BioPharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. AzurRx BioPharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

366 Future Performance

 How is AzurRx BioPharma expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
39.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AzurRx BioPharma expected to grow at an attractive rate?
  • AzurRx BioPharma's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • AzurRx BioPharma's earnings growth is expected to exceed the Germany market average.
  • Unable to compare AzurRx BioPharma's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:366 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:366 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 39.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:366 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:366 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 82 38 1
2023-12-31 35 0 1
2022-12-31 9 -20 1
2021-12-31 0 -19 2
2020-12-31 0 -16 3
2020-04-08
DB:366 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -14 -15
2019-09-30 -14 -18
2019-06-30 -13 -16
2019-03-31 -11 -15
2018-12-31 -11 -14
2018-09-30 -10 -12
2018-06-30 -9 -13
2018-03-31 -8 -12
2017-12-31 -7 -11
2017-09-30 -7 -14
2017-06-30 -7 -14
2017-03-31 -5 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AzurRx BioPharma's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if AzurRx BioPharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:366 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from AzurRx BioPharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:366 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.93 0.93 0.93 1.00
2023-12-31 -0.01 -0.01 -0.01 1.00
2022-12-31 -0.68 -0.68 -0.68 1.00
2021-12-31 -0.56 -0.44 -0.67 2.00
2020-12-31 -0.51 -0.40 -0.61 3.00
2020-04-08
DB:366 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.68
2019-09-30 -0.89
2019-06-30 -0.90
2019-03-31 -0.87
2018-12-31 -0.88
2018-09-30 -0.85
2018-06-30 -0.99
2018-03-31 -1.05
2017-12-31 -1.04
2017-09-30 -1.42
2017-06-30 -1.64
2017-03-31 -1.99

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AzurRx BioPharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess AzurRx BioPharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AzurRx BioPharma has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

366 Past Performance

  How has AzurRx BioPharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AzurRx BioPharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AzurRx BioPharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare AzurRx BioPharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AzurRx BioPharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
AzurRx BioPharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AzurRx BioPharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:366 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -15.18 6.06 8.68
2019-09-30 -17.92 9.39 8.28
2019-06-30 -16.30 8.83 7.24
2019-03-31 -14.56 8.80 5.43
2018-12-31 -13.53 7.45 5.77
2018-09-30 -11.99 7.52 3.92
2018-06-30 -12.56 8.21 3.72
2018-03-31 -11.92 7.43 3.54
2017-12-31 -11.10 7.69 2.40
2017-09-30 -14.25 7.60 2.47
2017-06-30 -14.31 6.14 2.25
2017-03-31 -15.41 5.64 2.34
2016-12-31 -14.59 4.13 2.50
2016-09-30 -9.63 2.79 1.93
2016-06-30 -8.30 3.30 1.55
2016-03-31 -6.73 3.23 1.77
2015-12-31 -5.93 3.33 1.40
2015-09-30 -6.22 3.40 1.91
2015-06-30 -5.30 3.13 1.73
2015-03-31 -3.33 2.47 1.01
2014-12-31 -2.37 1.87 1.05
2013-12-31 -1.01 0.54 0.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AzurRx BioPharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if AzurRx BioPharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if AzurRx BioPharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AzurRx BioPharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AzurRx BioPharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

366 Health

 How is AzurRx BioPharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AzurRx BioPharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AzurRx BioPharma's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • AzurRx BioPharma has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AzurRx BioPharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AzurRx BioPharma Company Filings, last reported 3 months ago.

DB:366 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 4.62 1.52 0.18
2019-09-30 3.20 1.95 1.55
2019-06-30 2.95 1.90 1.31
2019-03-31 2.71 1.89 0.41
2018-12-31 4.47 0.26 1.11
2018-09-30 5.53 0.00 4.43
2018-06-30 7.63 0.31 7.42
2018-03-31 1.10 0.32 0.57
2017-12-31 1.66 0.42 0.57
2017-09-30 2.80 0.34 2.95
2017-06-30 4.64 0.67 3.83
2017-03-31 1.47 0.08 0.53
2016-12-31 3.21 0.16 1.77
2016-09-30 -12.37 9.93 0.13
2016-06-30 -9.23 9.24 1.39
2016-03-31 -5.42 7.46 0.21
2015-12-31 -3.63 6.58 0.64
2015-09-30
2015-06-30 -0.14 2.93 0.24
2015-03-31 2.64 1.05 0.22
2014-12-31 2.64 1.05 0.22
2013-12-31 0.05 0.20 0.05
  • AzurRx BioPharma's level of debt (32.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (39.8% vs 32.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • AzurRx BioPharma has less than a year of cash runway based on current free cash flow.
  • AzurRx BioPharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 35.9% each year.
X
Financial health checks
We assess AzurRx BioPharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AzurRx BioPharma has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

366 Dividends

 What is AzurRx BioPharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AzurRx BioPharma dividends.
If you bought €2,000 of AzurRx BioPharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AzurRx BioPharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AzurRx BioPharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:366 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:366 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AzurRx BioPharma has not reported any payouts.
  • Unable to verify if AzurRx BioPharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AzurRx BioPharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AzurRx BioPharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess AzurRx BioPharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AzurRx BioPharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AzurRx BioPharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

366 Management

 What is the CEO of AzurRx BioPharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
James Sapirstein
COMPENSATION $687,487
AGE 58
TENURE AS CEO 0.5 years
CEO Bio

Mr. James R. Sapirstein, R.Ph., M.B.A. serves as the President, Chief Executive Officer and Non-Independent Director of AzurRx BioPharma, Inc. since October 8, 2019. Mr. Sapirstein has been Executive Chairman of Marizyme Incorporated since December 10, 2018. He is an Independent Director of Enochian Biosciences Inc. since March 2018. He served as an Independent Director of NanoViricides, Inc. since November 1, 2018 until February 10, 2020. He was the Chief Executive Officer of ContraVir Pharmaceuticals, Inc. until October 3, 2018 and served as Director of ContraVir Pharmaceuticals, Inc. since March 19, 2014. He served as Strategic Advisor of Muscle Pharm Corp. He served as the Chief Executive Officer of Alliqua Biomedical, Inc./Alliqua Therapeutics from February 5, 2013 to March 14, 2014. He is a highly-regarded pharmaceutical industry executive in building companies and leading the commercial launch of nearly two dozen prescription drugs in the fields of CNS, infectious disease, and cancer. He served as Strategic Advisor of Tobira Therapeutics, Inc. He served as Strategic Advisor of HIV/AIDS Market for Therapeutic Nutritional Products - MuscleGel and Re-con at Muscle Pharm Corp. since February 2011. He served as Chief Executive Officer of Alliqua, Inc. from October 1, 2012 to February 2013 and as its President from November 2012 to February 2013. He served as the Chief Executive Officer and President of Tobira Therapeutics, Inc. from August 2007 to April 4, 2011. He launched several HIV/AIDS agents worldwide in the biotechnology and pharmaceutical industry. He served as the Head of International HIV business of at Bristol-Myers Squibb as well working in their Infectious Disease marketing teams. He joined Serono in 2002. He served as an Executive Vice President of Metabolic & Endocrinology of Serono Inc., where he gained his experience working with biological products. In 2002, he accepted the position of Executive Vice President for Serono Laboratories, where he led a team of over 100 professionals to rebuild a struggling HIV and pediatric growth hormone business. He had positions of increasing responsibility at Gilead Sciences’ Viread®, Bristol-Myers Squibb, Hoffmann-LaRoche Ltd. and Eli Lilly and Company. Beginning in 2000, he led and developed the global marketing strategy for Gilead’s flagship HIV drug Viread. He played an instrumental role in the development of the drug combination strategy that resulted in Gilead’s acquisition of Triangle’s nucleoside portfolio. He served as the Chairman of BioNJ Inc., from February 9, 2017 to February 2019 and has been its Trustee since April 29, 2015. He had been Executive Vice Chairman of the Board at RespireRx Pharmaceuticals Inc. since December 28, 2018 until December 20, 2019 and served as its Director since September 03, 2014 until December 20, 2019. He is also a Director of Leading BioSciences Inc. since October 30, 2018. He has been an Independent Director of Cortex Pharmaceuticals, Inc. since September 2014. He serves as a Member of the Board of Directors of Clinical Supplies Management, Inc. He serves as an Advisory Board Director at the Fairleigh Dickinson School of Pharmacy. He served as a Member of the Advisory Board at MusclePharm Corp. He served as a Director at Probility Media Corporation (Panther Biotechnology, Inc.) since May 20, 2014 and its Scientific Advisory Board Member since November 07, 2016. He served as a Member of the Advisory Board at Muscle Pharm Corp. He served as a Director of Tobira Therapeutics, Inc. He served as a Director of Alliqua, Inc. from October 1, 2012 to February 2013. He served as a Director of BIO’s Emerging Company Board. He received an MBA from Fairleigh Dickinson University in 1997, and a BS (Pharmacy) from Rutgers University in 1984.

CEO Compensation
  • Insufficient data for James to compare compensation growth.
  • James's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the AzurRx BioPharma management team in years:

1.2
Average Tenure
58
Average Age
  • The average tenure for the AzurRx BioPharma management team is less than 2 years, this suggests a new team.
Management Team

James Sapirstein

TITLE
CEO, President & Non-Independent Director
COMPENSATION
$687K
AGE
58
TENURE
0.5 yrs

Jim Pennington

TITLE
Chief Medical Officer
COMPENSATION
$441K
AGE
76
TENURE
1.9 yrs

Martin Krusin

TITLE
Senior Vice President of Corporate Development
TENURE
6.3 yrs

Dan Schneiderman

TITLE
Chief Financial Officer
AGE
41
TENURE
0.3 yrs

Mathieu Schué

TITLE
Head of Laboratory
Board of Directors Tenure

Average tenure and age of the AzurRx BioPharma board of directors in years:

3.8
Average Tenure
65.5
Average Age
  • The tenure for the AzurRx BioPharma board of directors is about average.
Board of Directors

Ed Borkowski

TITLE
Independent Chairman of the Board
COMPENSATION
$109K
AGE
61
TENURE
4.6 yrs

James Sapirstein

TITLE
CEO, President & Non-Independent Director
COMPENSATION
$687K
AGE
58
TENURE
0.5 yrs

Alastair Riddell

TITLE
Independent Director
COMPENSATION
$109K
AGE
70
TENURE
4.6 yrs

Thijs Spoor

TITLE
Non-Independent Director
COMPENSATION
$848K
AGE
47
TENURE
5.9 yrs

Philip Toskes

TITLE
Member of Scientific Advisory Board

Fréderic Carrière

TITLE
Member of Scientific Advisory Board

René Laugier

TITLE
Member of Scientific Advisory Board

Mark Lowe

TITLE
Member of Scientific Advisory Board

Chuck Casamento

TITLE
Independent Director
COMPENSATION
$109K
AGE
74
TENURE
3.1 yrs

Vern Schramm

TITLE
Independent Director
COMPENSATION
$109K
AGE
78
TENURE
2.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess AzurRx BioPharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AzurRx BioPharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

366 News

Simply Wall St News

366 Company Info

Description

AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of therapeutic proteins under development, including MS1819-SD, a yeast derived recombinant lipase for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant b-lactamase enzyme combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea, as well as AZX1103, a b-lactamase enzyme combination. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.

Details
Name: AzurRx BioPharma, Inc.
366
Exchange: DB
Founded: 2014
$13,972,048
27,131,456
Website: http://www.azurrx.com
Address: AzurRx BioPharma, Inc.
Downstate Biotechnology Incubator,
Suite 304,
Brooklyn,
New York, 11226,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM AZRX Common Stock Nasdaq Capital Market US USD 11. Oct 2016
DB 366 Common Stock Deutsche Boerse AG DE EUR 11. Oct 2016
Number of employees
Current staff
Staff numbers
10
AzurRx BioPharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 23:12
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/07
Last earnings filing: 2020/03/30
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.